- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04583657
Intestinal Tolerance & Health Effects of Daily Consumption of Two Eggs With Fatty Acid Profile Related to Metabolic Disorders (Oil4Egg)
To Evaluate the Intestinal Tolerance and Health Effects of Daily Consumption of Two Eggs With a Particular Fatty Acid Profile on a Set of Parameters Related to Metabolic Disorders
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
This monocentric study is an interventional, randomized, double-blind, control study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids show interesting effects in the context of health. Indeed, some studies suggest positive effects on circulating lipids or inflammation associated with certain disorders such as diabetes, following the consumption of these fatty acids.
However, these fatty acids are not very present in the classic diet. Therefore, we have developped hens eggs naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids by changing the hens feed.
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
To do this, 80 subjects aged 35 to 75, sedentary (<2 hours of physical activity per week) and with abdominal obesity (> 94cm for men and> 80cm for women) were recruited and were divided into two groups: the control group (12 subjects consuming 2 classic eggs for 3 months per day) or the test group (12 subjects consuming 2 eggs enriched in omega per day for 3 months).
A medical examination with blood sampling was scheduled every month at baseline (Day 0), after one month (Day 30), after two months (Day 60) and at the end of the 3 months of intervention (Day90). During those visits, the following were monitored: glucose parameters, lipids parameters, fatty acid profile of red blood cells and plasma and safety parameters related to haematology, kidney and liver functions .
During these monthly medical visits patients also completed the questionnaires assessing intestinal tolerance (visual analogue scale showing 10 gastrointestinal symptoms), satiety (visual analog scale questionnaire) and well-being (36 items short form survey). Eating habits were monitored using a food diary. Additional parameters were measured only during the first and the last visit: coagulation, nutritional status, endothelial function and inflammation.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Louvain-La-Neuve, Belgique, 1348
- Center of Investigation in Clinical Nutrition
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Woman or man, aged of 35 to 75 years
- Abdominal obesity : waist circumference for men > 94cm and > 80cm for women
- Practicing < 2h of physical activity per week
Exclusion Criteria:
- Uncontrolled systolic blood pressure > 160/100mmHg
- For premenopausal women: pregnant or lactating women
- For menopausal women: less than 6 months of menopause
- Perimenopausal women with symptoms
- Type II diabetes (fasted glycaemia ≥ 126mg/dl or HbA1c ≥ 6.5%), Type I diabetes
- Medical history or actual cardiovascular disease (myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Familial history of premature cardiovascular incident (in male first degree relative < 55 years and in female first degree relative < 65 years; myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Medical history or actual liver, pancreas, kidney, pulmonary or gastrointestinal problem
- Thyroid disorder
- Cancer < 5 years before the screening visit
- Smokers or who have stopped smoking within 6 months before the screening visit
- Subject presenting allergy or food intolerance to eggs
- Subjects with psychiatric problems and/or using antipsychotics
- Drug addiction problem
- Recent change of body weight > 5kg (< 3 months before the screening visit)
Within 3 months before the screening visit, change in the chronic (> 7 days in a row) intake or dosage of drug(s) or product(s) modifying
- The glucose or lipid metabolism
- The blood pressure and heart rate
- Intestinal tolerance
- Hepatic, pancreas or kidney functions
- Satiety
- The inflammatory status
- Current or recent (< 3 months before the screening visit) intake of dietary supplements rich in n-3 polyunsaturated fatty acid
- Vegan diet
- Consumption of fish > 3 times per week
- Subjects who drink more than 3 glasses of alcohol per day (> 30 g of alcohol per day)
- LDL > 159 mg/dl or total cholesterol > 239 mg/dl or triglyceride > 200 mg/dl or HDL < 40 mg/dl
- Docosahexaenoic acid in red blood cell phospholipids > 8 %
- Subjects having participated to another clinical trial < 1 month before the screening test visit
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Control
Consumption of two "classical eggs" per day during three months.
The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%.
|
Consumption of two eggs (control or test) per day during three months
|
|
Expérimental: Test
Consumption of two test eggs per day during three months.
These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%,
total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
|
Consumption of two eggs (control or test) per day during three months
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glycated haemoglobin (HbA1c)
Délai: Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Glycated haemoglobin (HbA1c) in blood samples
|
Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glucose
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Insulin
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Homeostatic model assessment (HOMA)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quantitative insulin sensitivity check index (QUICKI)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Triglycerides
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Total cholesterol
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
low-density lipoprotein (LDL) cholesterol
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
high-density lipoprotein (HDL) cholesterol
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
non-high-density lipoprotein cholesterol (non-HDL)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern in red blood cells
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern plasma
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Urea
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Uric acid
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Creatinine
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Glomerular filtration rate (GFR)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Sodium (Na)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Potassium (K)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Chlore (Cl)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Phosphate (P)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alanine transaminase (ALAT)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Aspartate aminotransferase (ASAT)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Gamma-glutamyl transferase (GGT)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alkaline phosphatase (ALP)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lipase
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haemoglobin
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular volume (MCV)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular hemoglobin concentration (MCHC)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Red blood cells
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
White blood cells
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Blood cell count
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reticulocytes
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haematocrit
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Body weight
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Waist circumference
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Hip circumference
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fat mass
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lean mass
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Visceral fat mass
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
International normalized ratio (INR)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Activated clotting time (ACT)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Iron
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Transferrin
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Ferritin
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
% transferrin saturation
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Vitamin B12
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
25-hydroxy-vitamin D
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Protein
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Albumin
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
C-reactive protein (CRP)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-6
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-1b
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Tumor necrosis factor alpha (TNFa)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Oxidized low-density lipoprotein (LDLox)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Nitrosylated hemoglobin (HbNO)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Satiety
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Intestinal tolerance
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quality of life 36-item short-form survey (SF36)
Délai: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
SF36 questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reactive hyperemia index (LnRHI)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Augmentation index normalized for heart rate (AI@75bpm)
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Systolic blood pressure
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Diastolic blood pressure
Délai: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Glycated haemoglobin (HbA1c)
Délai: Day 30 (visit 2) and Day 60 (visit 3)
|
Glycated haemoglobin in blood sample
|
Day 30 (visit 2) and Day 60 (visit 3)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Yvan Larondelle, Prof, Université Catholique de Louvain
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Oil4Egg
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .